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Summary 
The fibrotic and antiapoptotic effects of insulin-like growth factors (IGF) are mediated by type I IGR receptor 
(IGF-1R). IGFs could play a role in intestinal stricturing and in the maintenance of inflammation in Crohn's 
disease (CD). We aimed to describe IGF-1R expression in CD intestinal lesions, to compare it to other intestinal 
inflammatory diseases and to correlate it with fibrosis and apoptosis. IGF-1R expression and apoptosis (active 
caspase-3) were studied by immunohistochemistry. Surgical intestinal specimens [17 CD, nine controls, six 
diverticulitis and four ulcerative colitis (UC)] were used. IGF-1R was expressed transmurally mainly by 
inflammatory cells (IC) and smooth muscle cells, both in diseased intestine and controls. IGF-1R positive IC 
were increased in the mucosa and the submucosa of CD (P < 0.007), and in involved areas compared to 
uninvolved areas (P = 0.03). In UC, the number of IGF-1R positive IC was only increased in the mucosa, and 
was not different from controls in the submucosa. In diverticulitis, the number of IGF-1R positive IC did not 
differ from controls. In CD submucosa, IGF-1R expression in IC was inversely correlated with apoptosis in 
uninvolved areas (P = 0.01). Expression of IGF-1R in submucosal fibroblast-like cells, subserosal adipocytes 
and hypertrophic nervous plexi was specific for CD. We have shown a transmural altered expression of IGF-1R 
in CD. This may suggest a role for IGF-1R in the maintenance of chronic inflammation and stricture formation 
in CD. 
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Introduction 
Crohn's disease (CD) is a chronic inflammatory disorder of the digestive tract. Intestinal lesions of CD are 
characterized by a transmural inflammatory infiltrate, mucosal ulcerations and non-caseating granulomas. The 
precise mechanisms underlying this chronic inflammation are unknown, but the relative resistance of 
inflammatory cells (IC) to apoptosis may play a critical role [1,2]. Chronic inflammation of the bowel wall in 
CD may lead to stricture formation. These strictures are characterized by thickening of the intestinal wall, diffuse 
fibrosis, increased collagen deposition and smooth muscle cells hyperplasia [3]. This complication is the main 
reason for intestinal surgical resection in CD. 
Insulin-like growth factors 1 (IGF-1) and 2 (IGF-2) are potentially relevant mediators in the chronic 
inflammation characterizing CD because of their profibrogenic actions [4] and their antiapoptotic effect [5]. IGF-
1 and -2 mediate the majority of their biological actions through type I insulinlike growth factor receptor (IGF-
1R) [6]. IGF-1 increases collagen synthesis in rat intestinal smooth muscle cells [7]. Insulin at concentrations 
that activate IGF-1R is also able to stimulate collagen synthesis by fibroblasts isolated from the intestinal wall in 
CD [8]. IGFs stimulate proliferation of fibroblasts [9], myofibroblasts [10] and smooth muscle cells [11] in vitro. 
IGFs, through activation of IGF-1R, can protect several types of cells from apoptosis, including fibroblasts [12], 
muscle cells [13], lymphocytes [14] and colon carcinoma cells [15]. In contrast, decreased expression of IGF-1 
and IGF-1R in advanced atherosclerotic intima may contribute to apoptosis of smooth muscle cells leading to 
plaque weakening and rupture [16]. 
IGF-1 was detected by enzyme-linked immunosorbent assay (ELISA) in whole gut fluid lavage in 78.6% of 
patients with intestinal strictures associated with CD and other diseases versus 11.6% of controls [17]. Moreover, 
IGF-1 and IGF-2 mRNA were shown to be overexpressed in diseased intestine of CD compared to uninvolved 
areas and, for IGF-1 mRNA, mainly in strictured compared to ulcerated segments [18]. IGF-1 has been detected 
by immunohis-tochemistry in normal intestine in lamina propria mononuclear cells and in CD throughout the 
bowel wall, following the intensity of the inflammatory infiltrate [19]. Another study localized IGF-1 mRNA in 
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CD to immune cells of the lamina propria, fibroblast-like cells of the submucosa and muscularis propria of both 
normal-appearing and fibroinflammatory CD, whereas positive smooth muscle cells were seen only in 
fibroinflammatory regions [20]. 
IGF-1R is expressed in human intestinal smooth muscle cells [21] and in human colon adenocarcinoma cell line 
Caco2. IGF-1R is also present on T cells and its expression is increased in activated T cells [14]. In normal rat 
intestine, IGF-1R expression was localized mainly to the muscularis propria and the mucosa [22]. This 
expression of IGF-1R in the intestinal wall could be relevant to Crohn's disease through IGF's antiapoptotic and 
profibrotic actions. 
Our aims were to describe intestinal expression of IGF-1R in CD, to compare it with other inflammatory states 
[ulcerative colitis (UC) and diverticulitis] and to correlate it with fibrosis and apoptosis. 
Materials and methods 
We used paraffin-embedded surgical tissue fragments from patients undergoing intestinal resection for a 
complicated CD or UC, for diverticulitis and for colonic adenocarcinoma. From our hospital archives of 
pathology, we selected 17 cases of colonic CD, six diverticulitis, four UC and nine colon carcinoma patients. 
The slides used for diagnosis of CD were reviewed in order to identify histologically involved (n = 17) or 
uninvolved areas (n = 15). For 15 cases of CD a tissue sample was selected in both involved and uninvolved 
areas. The corresponding paraffin-embedded bloc was used. Normal tissue from colonic resections for 
adenocarcinoma was used as controls. Inflamed tissue from UC and diverticulitis was used as inflammatory 
controls. Serial sections were carried out for each paraffin bloc. 
Immunohistochemistry for IGF-1R and active caspase-3 
Tissue slides were deparaffinized, rehydrated, preincubated in goat serum for 30 min and then incubated with 
primary antibody at room temperature for 2 h at a 1:75 dilution for anti-IGF-1R (IGF-1Rα, Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) and for 30 min at a 1:700 dilution for anticaspase3 (rabbit 
antihuman/mouse caspase-3 active, R&D Systems, Oxon, UK). Sections were then incubated for 30 min with the 
secondary biotinylated goat antirabbit antibody (Dako, Heverlee, Belgium). Binding of the primary antibody was 
detected with the streptavidine-HRP complex for 30 min. Each washing step was performed using phosphate 
buffered saline/Tween (3 × 5 min). Revelation occurred after an 8-min exposure with DAB (Dako) for IGF-1R 
and 30 min with AEC (Dako) for caspase. Slides were counterstained with haematoxylin for 10 s. 
Negative controls for IGF-1R consisted in neutralizing the primary antibody by preabsorption (for 2 h at room 
temperature) with an excess (fivefold by weight) of blocking peptide (Santa Cruz Biotechnology). For caspase-3 




IGF-1R immunostaining was analysed semiquantitatively by counting positive IC with the help of a 
computerized image-analysis system at a magnification of × 400. Because of a clustered distribution of IGF-1R-
positive IC, a mean count of three highly stained areas ('hot spots') was performed as described previously [23]. 
For each slide, three fields were captured in both the lamina propria and the submucosa and the IC were counted. 
A mean value was calculated for total and positive cells by field. Results were expressed as absolute and relative 
values (% of positive IC by field). Quantitative evaluation could not be performed on fibroblasts expressing IGF-
1R because these cells were absent from normal colon and scattered in CD. 
Active caspase-3 
Detection of apoptotic cells by immunohistochemistry with anti-active caspase-3 has been shown to be a 
validated method to study apoptosis [24]. Because active caspase-3 positive cells were distributed in a more 
diffuse way, the number of positive cells was evaluated for each layer (mucosa, submucosa) after viewing the 
whole slide (at magnification × 200). The slides used for this evaluation were immediately adjacent to the ones 
used for IGF-1R. The mean number of apoptotic IC cells by field was established. Relative values were 
calculated by dividing these numbers with the total number of IC by field. 
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Fibrosis evaluation (Table 1) 
Sections immediately adjacent to those used for immunohistochemistry were stained with Masson's trichrome 
and counterstained with haematoxylin to analyse collagen deposition. Fibrosis was evaluated using a 1-3 scale ( 
1, negative or discrete staining; 2, moderate staining; 3, strong staining). 
 
Table 1. Fibrosis status in involved (n = 17) and uninvolved (n = 15) areas of CD cases. Slides were stained 
with Masson's trichrome; fibrosis was evaluated using a scale from 1 to 3 (1: negative or discrete staining; 2: 
moderate staining; 3: strong staining) 
 1 2 3 
Uninvolved CD 15 0 0 
Involved CD 5 4 8 
CD: Crohn's disease. 
 
Statistics 
Absolute and relative numbers of IGF-1R positive cells were compared for significant difference using the 
Mann-Whitney U-test or Student's unpaired t-test with Welch correction (when the values passed normality, the 
Kolmogorov-Smirnov test), between CD, controls, UC and diverticulitis, and between involved and uninvolved 
CD. Paired comparison between involved and uninvolved areas of CD on the same patient was performed using 
Wilcoxon's matched-pairs signed-rank test. A correlation was searched between numbers (absolute and relative) 
of IGF-1R positive cells and caspase-3 positive cells, on one hand, or fibrosis score on the other hand, using 
Spearman's rank test. P < 0.05 was considered statistically significant. 
Results 
Various types of cells express IGF-1R 
Expression of IGF-1R was found in all the layers of the intestinal wall (mucosa, submucosa and muscularis 
propria) in both the normal and diseased intestine. The glandular epithelium, however, was negative in all the 
specimens analysed. Positivity was mainly cytoplasmic, but membranes were also stained. The majority of IGF-
1R positive cells had a morphology of inflammatory mononuclear cells (Fig. 1a). Inflammatory IGF-1R positive 
cells were observed within each layer of the intestinal wall. They were distributed in clusters following 
inflammatory infiltrate. Intraepithelial lymphocytes were sporadically positive. In the submucosa and subserosa, 
positive IC were frequently gathered around vessels and some were intravascular. Lymphoid follicles very rarely 
contained positive cells. In fibroinflammatory regions of CD, disorganized muscularis propria contained many 
positive IC within the septas and at the margins of the longitudinal and circular muscular layer. Both in diseased 
intestine and controls, smooth muscle cells also expressed IGF-1R. Positive smooth muscle cells were observed 
within vessel walls, muscularis mucosa and muscularis propria. IGF-1R positive fibroblast-like cells were 
recognized in the submucosa and subserosa in CD (Fig. 1b), but not in controls. These cells were encountered 
more often in fibrosed areas of CD. Finally, IGF-1R was also found in adipocytes within fibrolipomatous regions 
of CD (Fig. 1c) and, sporadically, in the hypertrophic nervous plexus of CD intestinal wall (Fig. 1d). 
Semi-quantitative analysis of inflammatory cells expressing IGF-1R and correlation with apoptosis and fibrosis 
The absolute number of inflammatory IGF-1R positive cells was increased in CD lamina propria (P = 0.007) and 
submucosa (P = 0.003) compared to controls (Table 2, Fig. 2a). In relative values, the difference between CD 
and controls was still significant in the lamina propria (P = 0.028) and borderline for significance in the 
submucosa (P = 0.066). In CD samples, the absolute number of IGF-1R positive IC was significantly higher in 
diseased areas compared to uninvolved areas of the same patients in the lamina propria (P = 0.03) (Fig. 1e,f) and 
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Table 2.  Mean number of inflammatory cells by field, mean absolute number and mean relative number of  IGF-
IR positive inflammatory cells by field (±s.d.) 
 Inflammatory cells 
 Lamina propria Submucosa 
  IGF-1R +  IGF-1R + 
 Total Absolute Relative Total Absolute Relative 
Controls 103.6 ± 19.3 9.9 ± 6.5 6.56 ± 6.2 13.7 ± 7.9 1 ± 0.9 9.1 ± 9.4 
Uninvolved CD 93.2 ± 45.3 15.5 ± 16.3 16.6 ± 17.5 18.2  ± 19.4 3.8 ± 6.6 17.7 ± 14.8 
Involved CD 131.1 ± 46.4 20.2  ± 11.4a 16.6 ± 8.9b 95.7 ± 75.7 12.7 ± 11.6c 15.6 ± 8 
UC 156.7 ± 54.3 19 ± 14.6 11.3  ± 4.9 63.9 ± 53.2 3.6 ± 2.5 9.1 ± 9.4 
Diverticulitis 104.1 ± 16.7 4.3 ± 3.6 4.1 ± 3.2 27.1 ± 17.5 2.5  ± 2.3 9.4 ± 5.3 
aCompared to controls (P = 0.007); compared to uninvolved CD using paired test (P = 0.03), compared to diverticulitis (P = 0.003). 
bCompared to controls (P = 0.028), compared to diverticulitis (P = 0.0004). cCompared to controls (P = 0.03); compared to uninvolved CD 
using paired test (P = 0.03); compared to UC (P = 0.03); compared to diverticulitis (P = 0.003). CD: Crohn's disease; UC: ulcerative 
colitis. 
 
Fig.1. IGF- 1R positive cells in Crohn's disease: (a) inflammatory cells, (b) fibroblast-like cell, (c) adipocytes 
and (d) hypertrophied nerve plexus. IGF-1R positive cells in the lamina propria of a specimen with Crohn's 
disease in an uninvolved area (e) and in a diseased area (f). 
 
 
The absolute number of IGF-1R positive IC in UC did not differ significantly from CD in the lamina propria, but 
was significantly lower than in involved CD in the submucosa (P = 0.03) (Fig. 2b). This was no longer 
significant in relative values. The absolute number of IGF- 1R positive cells was significantly lower in 
diverticulitis than in CD in the lamina propria (P = 0.003) and in the submucosa (P < 0.03) (Fig. 2c). In relative 
values, the number of IGF-1R positive cells in diverticulitis was still lower than in CD in the lamina propria (P = 
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0.0004) 
Most of the cells expressing active caspase-3 had a morphology of IC (Fig. 2d). Fibroblast-like cells positive for 
active caspase-3 were not identified. Table 3 shows the relative numbers of caspase-3 positive IC in the lamina 
propria and the submucosa, in the various conditions studied. There was no significant difference between 
controls, involved or uninvolved CD. The number of apoptotic cells (positive for active caspase-3) was 
correlated inversely to the number of IGF-1R-positive IC in uninvolved submucosa of CD (P = 0.01). In 
involved submucosa, there was only a trend towards this correlation (P = 0.09). No significant correlation was 
found in the lamina propria. 
Furthermore, in the submucosa of involved CD there was also a weak trend towards a correlation between the 
number of IGF-1R positive IC and the severity of fibrosis (P =  0.091). No correlation was found in the lamina 
propria. 
 
Fig. 2. Immunohistochemistry with an anti-IGF- 1R antibody: (a) increased number of IGF-1R positive 
inflammatory cells (in brown) in the mucosa and the submucosa in an involved area of Crohn's disease, (b) 
Increased number of IGF-1R positive inflammatory cells limited to the mucosa in an involved area of ulcerative 
colitis, (c) No overexpression of IGF-1R in diverticulitis, (d) Immunohistochemistry with an antiactive caspase 3 
antibody: positive inflammatory cells (in red) undergoing apoptosis in an uninvolved area of Crohn's disease. 
 
 
Table 3. Mean relative number (%) of apoptotic (active caspase-3 positive) inflammatory cells by field (±s.d.) 
Apoptotic inflammatory cells  
Lamina propria Submucosa 
Controls 103  ± 1.62 20.67 ± 25.12 
Uninvolved CD 2.83 ± 2.92 19.77 ± 30.44 
Involved CD 2.43 ± 2.97 15.61 ± 18.46 
CD: Crohn's disease. 
 
Discussion 
Our study describes, for the first time, the expression of IGF-1R in the bowel wall of CD patients. Previously, 
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expression of IGF-1 mRNA and pro-IGF-1 has been shown to be increased at sites of inflammation and fibrosis 
in active CD [25], suggesting a role for IGF-1 in this process. However, biological activity of IGF is dependent 
on the expression of IGF-1R. We show that various cells express IGF-1R protein throughout the bowel wall in 
controls and CD. Smooth muscle cells and immune cells are the most numerous. However, other cell types were 
found to express it in CD: fibroblast-fike cells in the fibrosed submucosa, adipocytes in fibrolipomatous tissue 
wrapping the intestine, also in the fibrosed area, and nerve cells in hypertrophic ganglia. 
The increase in absolute number of IGF-1R positive IC in lamina propria and submucosa of CD was parallel to 
the increase of the immunoinflammatory infiltrate. However, there was also an increase in the proportion 
(relative numbers) of IC positive for IGF-1R in CD. This may suggest a true overexpression of IGF-1R in the 
lamina propria and, to a lesser extent, in the submucosa of CD. One of the mechanisms by which IGF-1R 
expression may contribute to the increase of the immunoinflammatory infiltrate is by inducing a resistance to 
apoptosis. It has been reported that IGF-1-mediated activation of PI3-kinase/Akt contributes to normal T cell 
survival [26] and that IGF-1R expression is increased in activated T cells, protecting them from Fas-induced 
apoptosis [14]. We found an inverse correlation between IGF-1R expression and apoptosis detected by caspase-3 
positivity in only CD submucosa, mainly in uninvolved areas. This may suggest that in the mucosa or when 
active inflammation is present the role of IGF-1R expression in protection against apoptosis is less prominent. 
The mechanisms of reduced apoptosis of IC in CD are still unclear, although some data show that a decrease in 
Fas signalling could be implicated [1]. However, functional studies would be necessary to demonstrate a specific 
role for IGF-1R in IC protection from apoptosis in CD. As well as an antiapoptotic effect, IGF-1 and -2 may also 
have a direct effect on lymphocytes proliferation, as has been shown with human activated peripheral blood T 
cells in vitro, in which this proliferative effect is correlated with the appearance of IGF-1R [27]. Along with this, 
in CD, double staining with CD3 and Ki67 identified an increased number of dividing T cells in submucosa and 
mus-cularis propria [28]. 
IGF-1R may also have a trophic effect in CD, potentially favouring fibrosis, particularly through its expression 
and activation on mesenchymal cells. The implication of the IGF system in fibrosis is also described in other 
diseases such as pulmonary fibrosis [29] and hepatic fibrosis [30]. We found a significant IGF-1R expression on 
fibroblast-like cells in submucosa and subserosa exclusively in CD samples. These CD fibroblasts may be 
stimulated by local IGF-1 to produce collagens. In inflammatory bowel disease, fibroblasts isolated from 
affected intestinal mucosa display faster doubling time and greater proliferation in response to mediators 
(including IGF-1) and secrete higher levels of collagen compared to control fibroblasts [31]. As well as this 
increased expression of IGF-1R in fibroblast-like cells in CD, our data also showed that numerous IGF-1R 
positive IC are found at margins of fibrosed muscularis propria and within septas. The means by which 
activation of IGF-1R on immunoinflammatory submucosal cells may favour fibrosis remains to be elucidated. 
The absence of significant correlation between the degree of fibrosis and the number of IGF-1R positive IC 
suggests that these cells do not play an exclusive or determinant role in this phenomenon. Overex-pression of 
IGF-1 and IGF-1R in IC, associated with fibrosis, has also been described in other pathologies such as 
fibroproliferative acute respiratory distress syndrome [32], interstitial lung disease [33] and fibrotic lesions of 
asbesto-sis [34]. 
Through its ability to promote cell proliferation, the IGF system may have a role in smooth muscle cell 
hyperplasia of the muscularis propria, which is a prominent feature of CD intestinal strictures. Mice homozygous 
for IGF-1R null mutant gene have generalized organ hypoplasia including muscles [35], whereas SMP8-IGF-1 
transgenic mice, which specifically overexpress IGF-1 in alpha-smooth muscle actin positive cells [36,37], 
exhibit a thickened intestinal muscularis propria [37]. In CD, IGF-1 local intestinal overexpres-sion could act in 
an autocrine way on IGF-1R positive smooth muscle cells to stimulate their proliferation or in a paracrine way 
when it is produced by fibroblasts [20] and IC [19]. In our study, we observed an important expression of IGF-
1R in smooth muscle cells from muscularis mucosae and muscularis propria, without a dramatic difference 
between normal and CD intestine, even in strictured areas. However, this constitutively high degree of IGF-1R 
expression in the muscularis propria together with previously demonstrated increased expression of IGF-1 may 
suggest a role for IGF-1R hyperactivation in muscularis propria hyperplasia observed in strictures of CD. 
Overexpression of IGF-1R was also found in the lamina propria in UC, another chronic inflammatory bowel 
disease (Fig. 2b). In this disease, however, the overexpression of IGF-1R was limited to this layer as no 
overexpression was found in the submucosa or muscularis propria. This is in keeping with the pure mucosal, and 
not transmural, involvement characterizing UC. In contrast, in diverticulitis, an acute inflammatory disorder of 
the colon, no overexpression of IGF-1R was found in any of the layers of the bowel wall (Fig. 2c). 
Finally, another specific overexpression of IGF-1R was found in two pathological features often associated with 
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CD: adipous cells in peri-intestinal fibrolipomatous areas and hypertrophic intestinal nerve plexi. Interestingly, 
adipocytes and myocytes derive from a common precursor and IGF-1 promotes the differentiation of both cell 
types [38], Moreover, it has been shown that macroscopic intestinal fat-wrapping in CD is correlated with 
transmural inflammation, fibrosis and muscle thickening [39]. This suggests that IGF may have a role in the 
genesis of fibrolipomatous tissue in CD. However, the precise mechanism of this fibrolipomatosis in CD is 
largely unknown [40], although mesenteric PPARγ overexpression has been described [41]. Along the same 
lines, IGF-1 hyperactivation may be implicated in nerve hypertrophy in CD as it has been reported that 
transgenic mice overexpressing IGF-1 exhibit brain overgrowth [42]. 
In conclusion, we have shown an altered expression of IGF-1R transmurally in the bowel wall in CD, while it 
was present only in the mucosa in UC and absent in acute diverticulitis. This overexpression in the lamina 
propria of chronic inflammatory bowel diseases may participate in the maintenance of inflammation. In CD 
alone, altered expression in the other layers of the bowel wall, particularly increased numbers of IGF-1R positive 
IC and fibroblast-like cells in the submucosa and the muscularis propria, may also play a role in the bowel wall 
fibrosis characterizing this disease. New therapeutic strategies targeting IGF-1R activation may be a worthwhile 
study, aiming at controlling either chronic inflammation or fibrosis in CD. 
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